MGMT promoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas

Journal of Neuro-Oncology

Volumn 104, Issue 3, 2011, Pages 647-657

  Salehi, Fateme ^a,b   Scheithauer, Bernd W ^a   Kros, Johann M ^c   Lau, Queenie ^a   Fealey, Michael ^a   Erickson, Dana ^a   Kovacs, Kalman ^b   Horvath, Eva ^b   Lloyd, Ricardo V ^a  

^a MAYO CLINIC   (United States)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

MGMT immunoexpression; MGMT methylation; Pituitary carcinoma; Silent subtype 3 pituitary adenoma; Temozolomide susceptibility

Indexed keywords

CORTICOTROPIN; GROWTH HORMONE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROLACTIN; TEMOZOLOMIDE; THYROTROPIN;

ACTH SECRETING ADENOMA; ADOLESCENT; ADULT; ARTICLE; BRAIN CANCER; CANCER RESISTANCE; CLINICAL ARTICLE; CONTROLLED STUDY; DISSEMINATED CANCER; DNA METHYLATION; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCATION; GENETIC CORRELATION; GROWTH HORMONE SECRETING ADENOMA; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; HYPOPHYSIS CARCINOMA; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS POTENTIAL; MGMT GENE; ONCOGENE; PHENOTYPE; PROLACTINOMA; PROMOTER REGION; THYROTROPIN SECRETING ADENOMA;

ADENOMA; ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; CARCINOMA; DACARBAZINE; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; PITUITARY NEOPLASMS; PROMOTER REGIONS, GENETIC; STATISTICS AS TOPIC; YOUNG ADULT;

EID: 80052627802     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-011-0532-6     Document Type: Article

References (55)

1. S Byrne C Karapetis N Vrodos 2009 A novel use of temozolomide in a patient with malignant prolactinoma J Clin Neurosci 16 1694 1696 19818629 10.1016/j.jocn.2009.05.013
2. C Hagen HD Schroeder S Hansen C Hagen M Andersen 2009 Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy Eur J Endocrinol 161 631 637 19654234 10.1530/EJE-09-0389 1:CAS:528:DC%2BD1MXhtlOit7nN
3. A Takeshita N Inoshita M Taguchi C Okuda N Fukuhara K Oyama K Ohashi T Sano Y Takeuchi S Yamada 2009 High incidence of low O(6)-methylguanine DNA methyltransferase expression in invasive macroadenomas of Cushing's disease Eur J Endocrinol 161 553 559 19589911 10.1530/EJE-09-0414 1:CAS:528: DC%2BD1MXhtlOit7jN
4. LV Syro BW Scheithauer LD Ortiz CE Fadul E Horvath F Rotondo K Kovacs 2009 Effect of temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma Hormones (Athens) 8 303 306
5. LV Syro H Uribe LC Penagos LD Ortiz CE Fadul E Horvath K Kovacs 2006 Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm Clin Endocrinol (Oxf) 65 552 553 10.1111/j.1365-2265.2006.02653.x (Pubitemid 44414285)
6. VJ Moyes G Alusi HI Sabin J Evanson DM Berney K Kovacs JP Monson PN Plowman WM Drake 2009 Treatment of Nelson's syndrome with temozolomide Eur J Endocrinol 160 115 119 18984772 10.1530/EJE-08-0557 1:CAS:528: DC%2BD1MXhsVOhsb%2FJ
7. S Mohammed K Kovacs W Mason H Smyth MD Cusimano 2009 Use of temozolomide in aggressive pituitary tumors: case report Neurosurgery 64 E773 E774 19349807 10.1227/01.NEU.0000339115.12803.4E discussion E774
8. M Debono C Bridgewater R Ross J Newell-Price 2008 Treating an aggressive prolactinoma in a patient with MEN 1: beneficial response to temozolomide Endocr Abstr 15 188
9. K Kovacs E Horvath LV Syro H Uribe LC Penagos LD Ortiz CE Fadul 2007 Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: Morphological findings Hum Pathol 38 185 189 17056093 10.1016/j.humpath.2006.07.014 1:CAS:528:DC%2BD28XhtleisrfE (Pubitemid 44880216)
10. K Kovacs BW Scheithauer M Lombardero RE McLendon LV Syro H Uribe LD Ortiz LC Penagos 2008 MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy Acta Neuropathol 115 261 262 17926052 10.1007/s00401-007-0279-5
11. OL Chinot M Barrie S Fuentes N Eudes S Lancelot P Metellus X Muracciole D Braguer L Ouafik PM Martin H Dufour D Figarella-Branger 2007 Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide J Clin Oncol 25 1470 1475 17442989 10.1200/JCO.2006.07.4807 1:CAS:528: DC%2BD2sXlsVyntbo%3D (Pubitemid 46733073)
12. ME Hegi AC Diserens T Gorlia MF Hamou N de Tribolet M Weller JM Kros JA Hainfellner W Mason L Mariani JE Bromberg P Hau RO Mirimanoff JG Cairncross RC Janzer R Stupp 2005 MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 352 997 1003 15758010 10.1056/NEJMoa043331 1:CAS:528:DC%2BD2MXit1Wktro%3D (Pubitemid 40349502)
13. ZM Bush JA Longtine T Cunningham D Schiff JA Jane Jr ML Vance MO Thorner ER Laws Jr MB Lopes 2010 Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O6-methylguanine methyltransferase (MGMT) promoter methylation and expression J Clin Endocrinol Metab 95 E280 290 20668043 10.1210/jc.2010-0441
14. G Raverot N Sturm F de Fraipont M Muller S Salenave P Caron O Chabre P Chanson C Cortet-Rudelli R Assaker H Dufour S Gaillard P Francois E Jouanneau JG Passagia M Bernier A Cornelius D Figarella-Branger J Trouillas F Borson-Chazot T Brue 2010 Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience J Clin Endocrinol Metab 95 4592 4599 20660056 10.1210/jc.2010-0644 1:CAS:528:DC%2BC3cXhtlCktLvM
15. M Esteller SR Hamilton PC Burger SB Baylin JG Herman 1999 Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia Cancer Res 59 793 797 10029064 1:CAS:528:DyaK1MXht1Sjurk%3D (Pubitemid 29086728)
16. H Soejima W Zhao T Mukai 2005 Epigenetic silencing of the MGMT gene in cancer Biochem Cell Biol 83 429 437 16094446 10.1139/o05-140 1:CAS:528:DC%2BD2MXhtVGlsbvO (Pubitemid 41626761)
17. RO Pieper 1997 Understanding and manipulating O6-methylguanine-DNA methyltransferase expression Pharmacol Ther 74 285 297 9352585 10.1016/S0163-7258(97)00003-X 1:CAS:528:DyaK2sXmsFCgs7c%3D (Pubitemid 27425351)
18. K Tano S Shiota J Collier RS Foote S Mitra 1990 Isolation and structural characterization of a cDNA clone encoding the human DNA repair protein for O6-alkylguanine Proc Natl Acad Sci USA 87 686 690 2405387 10.1073/pnas.87.2.686 1:CAS:528:DyaK3cXkvFaht7s%3D
19. RS Day III CH Ziolkowski DA Scudiero SA Meyer AS Lubiniecki AJ Girardi SM Galloway GD Bynum 1980 Defective repair of alkylated DNA by human tumour and SV40-transformed human cell strains Nature 288 724 727 6256643 10.1038/288724a0 1:CAS:528:DyaL3MXhtF2ju7w%3D (Pubitemid 11168534)
20. ME Hegi AC Diserens S Godard PY Dietrich L Regli S Ostermann P Otten G Van Melle N de Tribolet R Stupp 2004 Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide Clin Cancer Res 10 1871 1874 15041700 10.1158/1078-0432.CCR-03-0384 1:CAS:528:DC%2BD2cXisVGltbY%3D (Pubitemid 38375541)
21. M Preusser R Charles Janzer J Felsberg G Reifenberger MF Hamou AC Diserens R Stupp T Gorlia C Marosi H Heinzl JA Hainfellner M Hegi 2008 Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker Brain Pathol 18 520 532 18400046 1:CAS:528:DC%2BD1cXht1CjtLvM
22. C Piperi MS Themistocleous GA Papavassiliou E Farmaki G Levidou P Korkolopoulou C Adamopoulos AG Papavassiliou 2010 High incidence of MGMT and RARbeta promoter methylation in primary glioblastomas: association with histopathological characteristics, inflammatory mediators and clinical outcome Mol Med 16 1 9 19809523 10.2119/molmed.2009.00140 1:CAS:528: DC%2BC3cXmtVOkug%3D%3D
23. JI Kim JT Suh KU Choi HJ Kang DH Shin IS Lee TY Moon WT Kim 2009 Inactivation of O6-methylguanine-DNA methyltransferase in soft tissue sarcomas: association with K-ras mutations Hum Pathol 40 934 941 19356788 10.1016/j.humpath.2009.01.005 1:CAS:528:DC%2BD1MXnt1CksLc%3D
24. S Jarmalaite F Jankevicius K Kurgonaite K Suziedelis P Mutanen K Husgafvel-Pursiainen 2008 Promoter hypermethylation in tumour suppressor genes shows association with stage, grade and invasiveness of bladder cancer Oncology 75 145 151 18824877 10.1159/000158665 1:CAS:528:DC%2BD1cXhsVKju7zN
25. AP Terra EF Murta PJ Maluf OL Caballero M Brait SJ Adad 2007 Aberrant promoter methylation can be useful as a marker of recurrent disease in patients with cervical intraepithelial neoplasia grade III Tumori 93 572 579 18338492 1:CAS:528:DC%2BD1cXitVOiurs%3D (Pubitemid 351158068)
26. MD Williams N Chakravarti MS Kies S Maruya JN Myers JC Haviland RS Weber R Lotan AK El-Naggar 2006 Implications of methylation patterns of cancer genes in salivary gland tumors Clin Cancer Res 12 7353 7358 17189407 10.1158/1078-0432.CCR-06-1272 1:CAS:528:DC%2BD28XhtlCrtr%2FP (Pubitemid 46095408)
27. U Schagdarsurengin O Gimm H Dralle C Hoang-Vu R Dammann 2006 CpG island methylation of tumor-related promoters occurs preferentially in undifferentiated carcinoma Thyroid 16 633 642 16889486 10.1089/thy.2006.16.633 1:CAS:528:DC%2BD28XnslOjt7g%3D
28. K Kawaguchi Y Oda T Saito H Yamamoto T Takahira C Kobayashi S Tamiya N Tateishi Y Iwamoto M Tsuneyoshi 2006 DNA hypermethylation status of multiple genes in soft tissue sarcomas Mod Pathol 19 106 114 16258501 10.1038/modpathol.3800502 1:CAS:528:DC%2BD2MXhtlSqu7zJ (Pubitemid 43250985)
29. J Brabender H Usadel R Metzger PM Schneider J Park D Salonga DD Tsao-Wei S Groshen RV Lord N Takebe S Schneider AH Holscher KD Danenberg PV Danenberg 2003 Quantitative O(6)-methylguanine DNA methyltransferase methylation analysis in curatively resected non-small cell lung cancer: associations with clinical outcome Clin Cancer Res 9 223 227 12538473 1:CAS:528:DC%2BD3sXnt1OksQ%3D%3D (Pubitemid 36109737)
30. S Nakasu T Fukami J Jito M Matsuda 2007 Prognostic significance of loss of O6-methylguanine-DNA methyltransferase expression in supratentorial diffuse low-grade astrocytoma Surg Neurol 68 603 608 17825378 10.1016/j.surneu.2006.12. 053 discussion 608-9 (Pubitemid 350160837)
31. WA Cooper MR Kohonen-Corish C Chan SY Kwun B McCaughan C Kennedy RL Sutherland CS Lee 2008 Prognostic significance of DNA repair proteins MLH1, MSH2 and MGMT expression in non-small-cell lung cancer and precursor lesions Histopathology 52 613 622 18370958 10.1111/j.1365-2559.2008.02999.x 1:STN:280:DC%2BD1c3ht1Khsw%3D%3D (Pubitemid 351442671)
32. Hamilton MG, Roldan G, Magliocco A, McIntyre JB, Parney I, Easaw JC (2010) Determination of the methylation status of MGMT in different regions within glioblastoma multiforme. J Neurooncol. doi: 10.1007/s11060-010-0307-5
33. D Erickson B Scheithauer J Atkinson E Horvath K Kovacs RV Lloyd WF Young Jr 2009 Silent subtype 3 pituitary adenoma: a clinicopathologic analysis of the Mayo Clinic experience Clin Endocrinol (Oxf) 71 92 99 10.1111/j.1365-2265.2008. 03514.x 1:STN:280:DC%2BD1MvptVyiuw%3D%3D
34. Q Lau B Scheithauer K Kovacs E Horvath LV Syro R Lloyd 2010 MGMT immunoexpression in aggressive pituitary adenoma and carcinoma Pituitary 13 367 379 20740317 10.1007/s11102-010-0249-0
35. ME Fealey BW Scheithauer E Horvath D Erickson K Kovacs R McLendon RV Lloyd 2010 MGMT immunoexpression in silent subtype 3 pituitary adenomas: possible therapeutic implications Endocr Pathol 21 161 165 20480258 10.1007/s12022-010-9120-0 1:CAS:528:DC%2BC3cXpslWnsbY%3D
36. JW Jeuken SJ Cornelissen M Vriezen MM Dekkers A Errami A Sijben SH Boots-Sprenger P Wesseling 2007 MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas Lab Invest 87 1055 1065 17700563 10.1038/labinvest.3700664 1:CAS:528:DC%2BD2sXhtVCrtLjF (Pubitemid 47429190)
37. M Esteller J Garcia-Foncillas E Andion SN Goodman OF Hidalgo V Vanaclocha SB Baylin JG Herman 2000 Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents N Engl J Med 343 1350 1354 11070098 10.1056/NEJM200011093431901 1:CAS:528:DC%2BD3cXosFOltLg%3D
38. MF Paz R Yaya-Tur I Rojas-Marcos G Reynes M Pollan L Aguirre-Cruz JL Garcia-Lopez J Piquer MJ Safont C Balana M Sanchez-Cespedes M Garcia-Villanueva L Arribas M Esteller 2004 CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas Clin Cancer Res 10 4933 4938 15297393 10.1158/1078-0432.CCR-04-0392 1:CAS:528:DC%2BD2cXmtlSisbc%3D (Pubitemid 39099766)
39. MJ Worsham KM Chen N Tiwari G Pals JP Schouten S Sethi MS Benninger 2006 Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma Arch Otolaryngol Head Neck Surg 132 409 415 16618910 10.1001/archotol.132.4.409
40. K Chen R Sawhney M Khan MS Benninger Z Hou S Sethi JK Stephen MJ Worsham 2007 Methylation of multiple genes as diagnostic and therapeutic markers in primary head and neck squamous cell carcinoma Arch Otolaryngol Head Neck Surg 133 1131 1138 18025318 10.1001/archotol.133.11.1131 (Pubitemid 350157026)
41. AI McCormack KL McDonald AJ Gill SJ Clark MG Burt KA Campbell WJ Braund NS Little RJ Cook AB Grossman BG Robinson RJ Clifton-Bligh 2009 Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours Clin Endocrinol (Oxf) 71 226 233 10.1111/j.1365-2265.2008.03487.x 1:CAS:528:DC%2BD1MXhtVSqt7bJ
42. S Sharma F Salehi BW Scheithauer F Rotondo LV Syro K Kovacs 2009 Role of MGMT in tumor development, progression, diagnosis, treatment and prognosis Anticancer Res 29 3759 3768 19846906 1:CAS:528:DC%2BD1MXhsVOlt7vJ
43. PF Wu KT Kuo LT Kuo YT Lin WC Lee YS Lu CH Yang RM Wu YK Tu JC Tasi HM Tseng SH Tseng AL Cheng CH Lin 2010 O(6)-Methylguanine-DNA methyltransferase expression and prognostic value in brain metastases of lung cancers Lung Cancer 68 484 490 19740564 10.1016/j.lungcan.2009.08.010
44. L Juillerat-Jeanneret CC Bernasconi C Bricod S Gros S Trepey J Benhattar RC Janzer 2008 Heterogeneity of human glioblastoma: glutathione-S-transferase and methylguanine-methyltransferase Cancer Invest 26 597 609 18584351 10.1080/07357900802072913 1:CAS:528:DC%2BD1cXnsl2rtL4%3D (Pubitemid 351918586)
45. VT Cao TY Jung S Jung SG Jin KS Moon IY Kim SS Kang CS Park KH Lee HJ Chae 2009 The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas Neurosurgery 65 866 875 19834398 10.1227/01.NEU.0000357325.90347.A1 discussion 875
46. EM Grasbon-Frodl FW Kreth M Ruiter O Schnell K Bise J Felsberg G Reifenberger JC Tonn HA Kretzschmar 2007 Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas Int J Cancer 121 2458 2464 17691113 10.1002/ijc.23020 1:CAS:528:DC%2BD2sXhtlShtbzM (Pubitemid 350022415)
47. JF Parkinson HR Wheeler A Clarkson CA McKenzie MT Biggs NS Little RJ Cook M Messina BG Robinson KL McDonald 2008 Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma J Neurooncol 87 71 78 18004504 10.1007/s11060-007-9486-0 1:CAS:528: DC%2BD1cXivFygtro%3D
48. GJ Kitange BL Carlson AC Mladek PA Decker MA Schroeder W Wu PT Grogan C Giannini KV Ballman JC Buckner CD James JN Sarkaria 2009 Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model J Neurooncol 92 23 31 19011762 10.1007/s11060-008-9737-8 1:CAS:528:DC%2BD1MXhtVGjtb0%3D
49. J Sheehan J Rainey J Nguyen R Grimsdale S Han 2010 Temozolomide-induced inhibition of pituitary adenoma cells J Neurosurg 114 354 358 20469984
50. JM Wu MJ Fackler MK Halushka DW Molavi ME Taylor WW Teo C Griffin J Fetting NE Davidson AM De Marzo JL Hicks D Chitale M Ladanyi S Sukumar P Argani 2008 Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases Clin Cancer Res 14 1938 1946 18381931 10.1158/1078-0432.CCR-07-4082 1:CAS:528:DC%2BD1cXkt1aktbg%3D (Pubitemid 351551102)
51. M Vecchi S Confalonieri P Nuciforo MA Vigano M Capra M Bianchi D Nicosia F Bianchi V Galimberti G Viale G Palermo A Riccardi R Campanini MG Daidone MA Pierotti S Pece PP Di Fiore 2008 Breast cancer metastases are molecularly distinct from their primary tumors Oncogene 27 2148 2158 17952122 10.1038/sj.onc.1210858 1:CAS:528:DC%2BD1cXktFCns7s%3D (Pubitemid 351483380)
52. A Zahedi GL Booth HS Smyth WE Farrell RN Clayton SL Asa S Ezzat 2001 Distinct clonal composition of primary and metastatic adrencorticotrophic hormone-producing pituitary carcinoma Clin Endocrinol (Oxf) 55 549 556 10.1046/j.1365-2265.2001.01322.x 1:STN:280:DC%2BD3MrntlWjtw%3D%3D (Pubitemid 32955495)
53. G Widhalm S Wolfsberger M Preusser A Woehrer MR Kotter T Czech C Marosi E Knosp 2009 O(6)-methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas: are progressive tumors potential candidates for temozolomide treatment? Cancer 115 1070 1080 19156926 10.1002/cncr.24053 1:CAS:528:DC%2BD1MXjs1Kju7o%3D
54. I Lavon D Fuchs D Zrihan G Efroni B Zelikovitch Y Fellig T Siegal 2007 Novel mechanism whereby nuclear factor kappaB mediates DNA damage repair through regulation of O(6)-methylguanine-DNA-methyltransferase Cancer Res 67 8952 8959 17875738 10.1158/0008-5472.CAN-06-3820 1:CAS:528:DC%2BD2sXhtVCit7nF (Pubitemid 47437473)
55. MD Blough MC Zlatescu JG Cairncross 2007 O6-methylguanine-DNA methyltransferase regulation by p53 in astrocytic cells Cancer Res 67 580 584 17234766 10.1158/0008-5472.CAN-06-2782 1:CAS:528:DC%2BD2sXmtVKksA%3D%3D (Pubitemid 46192195)